DUBLIN – Modern Biosciences plc (MBS) could earn up to £176 million (US$277 million) in up-front and milestone payments from an option and licensing deal with the Janssen Biotech Inc. arm of Johnson & Johnson that covers a series of preclinical bone-protective compounds in development for rheumatoid arthritis (RA) and potentially other indications.